Jain Global’s Cartesian Therapeutics RNAC Stock Holding History

Jain Global’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,724	Closed	-$121K	–	1583
2025 Q4	$121K	Buy	+16,724	New	+$135K	﹤0.01%	1094

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jain Global's RNAC Position: Q1 2026 in Review

Jain Global sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 16,724 shares — an estimated $121K sold.

Jain Global first reported a position in RNAC in Q4 2025 and held it in 1 quarter. The position peaked at $121K in Q4 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Jain Global reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
Jain Global sold 16,724 Cartesian Therapeutics shares in Q1 2026, an estimated $121K.
Jain Global first reported a position in Cartesian Therapeutics in Q4 2025 and held it in 1 quarter.
Jain Global's Cartesian Therapeutics position peaked at $121K in Q4 2025.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.